PRVA · Privia Health Group, Inc.

Track PRVA — free

$19.69 +0.07 (+0.36%) At close · Sep 30

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$2.52B

127.73M

Volume · Sep 30 1.34M Avg daily vol (3M) 1.21M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$2.36B

Trailing 12 months

Net income (TTM)

$26.30M

Trailing 12 months

Revenue growth YoY

+21.4%

Year over year

Operating margin

1.9%

Trailing 12 months

P / E (TTM)

89.2

Trailing earnings · reciprocal yield 1.1%

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$412.20M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.6%

Year over year · more shares

Price change (1Y)

-19.7%

Trailing year

Short interest

3.8%

Latest settlement · 4.0 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Privia Health delivered strong Q2 2026 results with 12.4% practice collections growth, 29% Adjusted EBITDA growth, and 310 bps of EBITDA margin expansion, and raised full-year 2026 guidance for attributed lives above the prior high end while lifting practice collections/GAAP revenue/care margin/platform contribution/EBITDA to the high or mid-to-high end of prior ranges.

Bullish

+ Adjusted EBITDA grew 29.1% YoY to $37.4M with margin expanding 310 bps
+ Raised full-year 2026 guidance for attributed lives above the high end, practice collections/GAAP revenue to the high end, and care margin/platform contribution/Adjusted EBITDA to the mid-to-high end of prior ranges
+ H1 2026 practice collections grew 13.4% to $1.88B with Adjusted EBITDA up 32.6% to $74.1M, supported by $412M cash and no debt

Bearish

− CMS may delay final MSSP reconciliation results for performance year 2025 until November, creating atypical year-end cash flow dynamics
− Free cash flow conversion is now constrained by full cash taxpayer status, with only 70-80% of Adjusted EBITDA expected to convert

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −14%

below

Price vs 50-day avg −10%

below

RSI (14) 36

neutral

MACD trend Positive

52-week position 6%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −4%

trailing

6-month return −14%

trailing

YTD return −17%

this year

Relative strength −27%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $22 › 200d $23 — 200d above 50d

Institutional flow Accumulating

+3% holders QoQ · +46 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.84% of float · ▼ -10.2% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

303 holders — near 3-yr high, broad support

Squeeze score 43

elevated · 0–100

Fundamentals

Strong

Revenue growth +22%

Y/Y

EPS growth +64%

Y/Y

Free cash flow $163.3M

Valuation P/E 89.6

rich

Quant / Vol

risk profile

Moderate

Volatility 32%

annualized · 1-yr

Max drawdown −32%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Aug 6, 2026

Adjusted EBITDA conversion to free cash flow · full-year Non-GAAP 70% – 80%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−14% Bearish

Price vs 50-day avg

−10% Bearish

RSI (14)

36 Neutral

MACD trend

Positive Bullish

52-week position

6% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $22 › 200d $23 — 200d above 50d

Institutional flow Accumulating

+3% holders QoQ · +46 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.84% of float · ▼ -10.2% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

303 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $19 Now $20 · 6% Range high $28

vs 200-day avg -14% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$74.1M	For the Six Months Ended June 30	—
Adjusted EBITDA Margin non-GAAP	28.4%	Six Months Ended June 30, 2026	—
Adjusted net income non-GAAP	$49.58M	Six Months Ended June 30, 2026	—
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic non-GAAP	$0.4	Six Months Ended June 30, 2026	—
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted non-GAAP	$0.38	Six Months Ended June 30, 2026	—
Attributed Lives (as of end of period)	1,647,000	Six Months Ended June 30, 2026	—
Care Margin non-GAAP	$260.9M	For the Six Months Ended June 30	—
Implemented Providers (as of end of period)	5,644	Six Months Ended June 30, 2026	—
Platform Contribution non-GAAP	$136M	For the Six Months Ended June 30	—
Platform Contribution Margin non-GAAP	52.1%	Six Months Ended June 30, 2026	—
Practice Collections	$1.88B	For the Six Months Ended June 30	—
Value-Based Care Attributed Lives	1,647,000	Three Months Ended June 30	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PRVA Privia Health Group, Inc. this stock	$2.52B	-17.3%	+22.3%	89.6	3.8%
VEEV Veeva Systems Inc	$45.44B	+24.8%	+28.1%	45.9	3.1%
TEM Tempus AI, Inc.	$15.34B	+39.8%	+83.4%	—	15.6%
PMDIY Pro Medicus Ltd./ADR	$12.20B	-29.7%	—	—	0.0%
BTSG BrightSpring Health Services, Inc.	$11.02B	+48.7%	+28.2%	33.8	5.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

303

% held: 96.9%
Net QoQ: +2.7M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

292

View

Short & Settlement

Short Interest Falling

Shares short

4.9M

Days to cover: 4.0d
Change: -554.4K sh

View

Short Volume

Short vol %

52%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.4K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

40.5%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Net income (FY)

$22.9M

EPS diluted: $0.18

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 18, 2026
This year: 11

View

Proposed Sales

Value

$588.6K

Shares: 21.3K
Filed: Jul 9, 2026

View

Exempt Offerings

Offering

Indefinite

Filed: Mar 11, 2020

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
PRVA	+0.8%	-4.3%	-13.6%	-4.3%	-17.3%
SPY	-1.2%	-0.4%	+13.1%	-0.4%	+12.1%
vs SPY	+2.0%	-3.9%	-26.7%	-3.9%	-29.3%

Key facts CIK 1759655 CUSIP 74276R102 13F (30d) 13 filings 9 filers Visit website Investor relations

PRVA · Privia Health Group, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance